Biomilq, a US-based biotechnology company has benefitted largely through Series A funding during which the establishment secured $21 million. The funding will be dedicated to the company’s goal of introducing cell-cultured human milk in the market.
Biomilq is women-led company aiming to embark breakthrough results in the fields of mammary biotechnology. With a team of highly skilled women, workforce with scientific expertise and mothers, is targeting specific concerns of breast feeding women and parents concerned about their baby’s health. The women-centric biotechnology company focuses primarily on nourishing healthier babies, supporting parents with a choice and ultimately contributing to a healthier and sustainable planet.
Commenting on the recent events, Kartik Dharmadhikari, Biomilq board director and Novo Holding’s partner said that the goal here is to positively influence community. Dharmadhikari added that the focus is on impacting the health, society and science. He also stated that the product portfolio of Biomilq has the potential to disrupt the conventional infant formula.